


MHC I & Hybridoma

The Challenge

To apply a multi-cohort immunization strategy with IPA's semi-solid hybridoma workflow with high throughput multiplexed flow cytometry screening, to deliver a diverse panel of paralogue-specific and species cross-reactive lead candidate sequences against a MHC I target, a historically difficult target class.


Delivering a diverse panel of lead candidate sequences



Program Summary

| Clones Screened | Initial Target Reactive Clones | Clones (meeting clients screening requirements) Sequenced | % of Clones with Unique Sequences | Lead Candidates Selected |
|-----------------|--------------------------------|---|-----------------------------------|--------------------------|
| 3840 | 182 | 37 | 92% | 22 |

Phylogenetic Relationship of Paralog Specific Top Clones



Conclusion

IPA's robust immunization schedules and semi-solid hybridoma workflow allowed for efficient NGS sequencing of parental clones leading to a diverse yet selective panel of lead candidates with an industry leading timeline.

For more information contact: info@ipatherapeutics.com

